The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Cancer Center at Illinois researcher unveils targeting technology for cancer immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Hua Wang, an assistant professor in the departments of Material Science & Engineering, Bioengineering, Materials Research Lab, and Biomedical and Translational Sciences, finetunes an important technology in biomaterial chemistry at the Cancer Center at Illinois, which could potentially make way for more potent cancer immunotherapies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Perspective

California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait. 
By Arie S. Belldegrun
Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account